PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) has announced the appointment of Tom Kassberg to its Board of Directors, along with his role on the Audit Committee, marking a significant addition to the company’s leadership team. Kassberg, a seasoned biotech executive, brings a wealth of experience from his current position as Chief Business Officer and Executive Vice President at Ultragenyx, a firm dedicated to developing treatments for rare and ultrarare genetic diseases.
Will Chou, M.D., president and CEO of Passage Bio, expressed enthusiasm about Kassberg joining the board, stating, “We are pleased to welcome Tom Kassberg to the Passage Bio Board of Directors, where he will play an influential role in driving our mission forward during this critical time for the organization.” Kassberg’s history of leading business development and strategic planning at Ultragenyx has positioned him as a key figure in advancing gene therapies for rare diseases. His expertise is expected to guide Passage Bio’s efforts in developing PBFT02 for various neurodegenerative disorders.
Kassberg has an impressive track record in the biotech sector. Before his tenure at Ultragenyx, he held executive roles at Proteolix, Inc., InterMune, Inc., and co-founded Plexxikon, where he spearheaded business and corporate development initiatives. His early career included strategic roles at SUGEN, facilitating its acquisition by Pharmacia, and at Bristol Myers Squibb in strategic planning and financial analysis.
In his statement, Kassberg shared his eagerness to join Passage Bio’s board: “I am excited to join the Passage Bio Board of Directors and contribute to the continued growth of the company. The remarkable progress of the PBFT02 program and opportunity to expand into additional indications highlight Passage Bio’s dedication to making a critical impact in the field of neurodegenerative diseases.”
Kassberg’s academic credentials include a B.A. in economics and management from Gustavus Adolphus College and an M.B.A. from Northwestern University’s Kellogg School of Management. His appointment is anticipated to bolster Passage Bio’s strategic initiatives and drive innovation in treatments for neurodegenerative diseases, offering hope to patients and families affected by these conditions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.